Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| smooth muscle cell | 18 studies | 32% ± 19% | |
| myofibroblast cell | 5 studies | 30% ± 16% | |
| microglial cell | 4 studies | 31% ± 10% | |
| pericyte | 4 studies | 24% ± 6% | |
| dendritic cell | 3 studies | 24% ± 6% |
Insufficient scRNA-seq data for expression of KCNMB1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 82% | 5424.74 | 201 / 245 | 99% | 20.12 | 496 / 502 |
| uterus | 94% | 9612.91 | 160 / 170 | 69% | 8.72 | 315 / 459 |
| bladder | 95% | 7584.81 | 20 / 21 | 66% | 3.99 | 334 / 504 |
| esophagus | 76% | 11934.86 | 1094 / 1445 | 81% | 5.52 | 149 / 183 |
| intestine | 76% | 10375.39 | 734 / 966 | 71% | 3.83 | 373 / 527 |
| stomach | 50% | 4295.37 | 179 / 359 | 81% | 7.88 | 232 / 286 |
| breast | 45% | 1151.08 | 206 / 459 | 86% | 4.33 | 957 / 1118 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.56 | 1 / 1 |
| blood vessel | 99% | 12492.06 | 1327 / 1335 | 0% | 0 | 0 / 0 |
| lung | 15% | 287.53 | 89 / 578 | 80% | 4.21 | 922 / 1155 |
| brain | 0% | 7.36 | 9 / 2642 | 86% | 4.71 | 608 / 705 |
| pancreas | 0% | 0 | 0 / 328 | 84% | 4.24 | 150 / 178 |
| kidney | 3% | 61.36 | 3 / 89 | 74% | 3.46 | 670 / 901 |
| thymus | 4% | 102.04 | 28 / 653 | 71% | 1.55 | 428 / 605 |
| ovary | 14% | 621.51 | 26 / 180 | 51% | 1.16 | 220 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 64% | 1.33 | 29 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 45% | 1.45 | 13 / 29 |
| skin | 5% | 87.98 | 88 / 1809 | 38% | 0.78 | 181 / 472 |
| adrenal gland | 0% | 5.74 | 1 / 258 | 39% | 1.43 | 90 / 230 |
| liver | 0% | 0 | 0 / 226 | 16% | 0.32 | 65 / 406 |
| adipose | 16% | 455.59 | 190 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 9% | 0.14 | 7 / 80 |
| heart | 2% | 38.68 | 16 / 861 | 0% | 0 | 0 / 0 |
| spleen | 1% | 20.93 | 3 / 241 | 0% | 0 | 0 / 0 |
| muscle | 1% | 11.31 | 5 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 6.04 | 2 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1901381 | Biological process | positive regulation of potassium ion transmembrane transport |
| GO_0006813 | Biological process | potassium ion transport |
| GO_1903413 | Biological process | cellular response to bile acid |
| GO_0042311 | Biological process | vasodilation |
| GO_0007268 | Biological process | chemical synaptic transmission |
| GO_0071361 | Biological process | cellular response to ethanol |
| GO_0071805 | Biological process | potassium ion transmembrane transport |
| GO_0005513 | Biological process | detection of calcium ion |
| GO_0071456 | Biological process | cellular response to hypoxia |
| GO_0045202 | Cellular component | synapse |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0008076 | Cellular component | voltage-gated potassium channel complex |
| GO_0015269 | Molecular function | calcium-activated potassium channel activity |
| GO_0015459 | Molecular function | potassium channel regulator activity |
| Gene name | KCNMB1 |
| Protein name | Calcium-activated potassium channel subunit beta-1 (BK channel subunit beta-1) (BKbeta) (BKbeta1) (Hbeta1) (Calcium-activated potassium channel, subfamily M subunit beta-1) (Calcium-activated potassium channel subunit beta) (Charybdotoxin receptor subunit beta-1) (K(VCA)beta-1) (Maxi K channel subunit beta-1) (Slo-beta-1) (Slo-beta) |
| Synonyms | |
| Description | FUNCTION: Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate. |
| Accessions | ENST00000521859.1 [Q16558-2] ENST00000274629.9 [Q16558-1] Q16558 |
